Henan Lingrui Pharmaceutical News

Henan Lingrui Pharmaceutical (600285.SH) plans to distribute a dividend of 0.8 yuan per share in 2023, with ex-rights and ex-dividends on June 20th.

Henan Lingrui Pharmaceutical (600285.SH) announced that the company's annual profit distribution plan for 2023 is to distribute RMB...per share.

Zhitong FinanceJun 13 05:34 ET

If EPS Growth Is Important To You, Henan Lingrui Pharmaceutical (SHSE:600285) Presents An Opportunity

For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to investors, even if it currently lacks a track record of revenue and profit. But the

Simply Wall StJun 11 18:29 ET

Henan Lingrui Pharmaceutical Leads Three Key Dividend Stocks In China

Yahoo FinanceJun 5 18:05 ET

Some directors and supervisors of Ling Rui Pharmaceutical (600285.SH) completed a shareholding reduction of 1861,000 shares

Ling Rui Pharmaceutical (600285.SH) announced that company director Wu Xizhen and supervisor Li Jin reduced their holdings of the company by a total of 18...

Zhitong FinanceMay 24 05:31 ET

Henan Lingrui Pharmaceutical Co., Ltd.'s (SHSE:600285) Stock Is Going Strong: Is the Market Following Fundamentals?

Henan Lingrui Pharmaceutical's (SHSE:600285) stock is up by a considerable 27% over the past three months. Since the market usually pay for a company's long-term fundamentals, we decided to study th

Simply Wall StMay 22 19:23 ET

Ling Rui Pharmaceutical (600285.SH): After implementing the holdings reduction, Xinrui Investment reduced its holdings by 1.92% of the company's shares

Gelonghui, May 14, 丨 Ling Rui Pharmaceutical (600285.SH) announced that recently, the company received a “Notice of Shareholding Reduction Results” from Xinrui Investment. As of May 14, 2024, Xinrui Investment had reduced its holdings of the company's shares by 10.867 million shares through bulk transactions, accounting for 1.92% of the company's total share capital before the implementation of the holdings reduction plan. The implementation of this holdings reduction plan was completed.

Gelonghui FinanceMay 14 06:42 ET

Lingrui Pharma Gets Green Light to Market Type 2 Diabetes Drug

Chinese drug regulator National Medical Products Administration granted a drug registration certificate to Henan Lingrui Pharmaceutical (SHA:600285) for its metformin hydrochloride extended-release ta

MT NewswiresMay 13 01:46 ET

Ling Rui Pharmaceutical (600285.SH): Metformin hydrochloride extended-release tablets obtained drug registration certificate

Gelonghui, May 10, 丨 Ling Rui Pharmaceutical (600285.SH) announced that the company recently received the “Drug Registration Certificate” for metformin hydrochloride extended-release tablets approved and issued by the State Drug Administration. Metformin hydrochloride sustained-release tablets are biguanide hypoglycemic agents, which can reduce the amount of glucose produced by the liver and absorption of glucose by the intestines, and increase insulin sensitivity and lower basal and post-meal blood sugar by increasing the intake and utilization of peripheral glucose.

Gelonghui FinanceMay 10 05:21 ET

Henan Lingrui Pharmaceutical Co., Ltd.'s (SHSE:600285) Share Price Boosted 27% But Its Business Prospects Need A Lift Too

Henan Lingrui Pharmaceutical Co., Ltd. (SHSE:600285) shares have continued their recent momentum with a 27% gain in the last month alone. Looking back a bit further, it's encouraging to see the sto

Simply Wall StMay 7 18:40 ET

Ling Rui Pharmaceutical (600285.SH): Xinrui Investment plans to reduce its holdings by no more than 1.92%

Gelonghui, May 7 | Ling Rui Pharmaceutical (600285.SH) announced that Xinrui Investment plans to reduce its holdings of the company's shares by no more than 1.92% of the company's total shares through centralized bidding and bulk trading through the Shanghai Stock Exchange trading system.

Gelonghui FinanceMay 7 05:35 ET

Is Henan Lingrui Pharmaceutical (SHSE:600285) A Risky Investment?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the permanent loss of capital.' So it might be obvious that you need to consider debt, whe

Simply Wall StApr 27 21:40 ET

Henan Lingrui Pharma Registers Chewable Asthma Drug in China

Henan Lingrui Pharmaceutical (SHA:600285) received a drug registration certificate from China's National Medical Products Administration (NMPA) for Montelukast, according to a Friday filing on the Sha

MT NewswiresApr 19 02:32 ET

Ling Rui Pharmaceutical (600285.SH) received the drug registration certificate for montelukast sodium chewable tablets

Ling Rui Pharmaceutical (600285.SH) issued an announcement. The company recently received approval and issuance from the State Drug Administration...

Zhitong FinanceApr 18 03:33 ET

Henan Lingrui Pharmaceutical (SHSE:600285) Stock Performs Better Than Its Underlying Earnings Growth Over Last Three Years

It might seem bad, but the worst that can happen when you buy a stock (without leverage) is that its share price goes to zero. But in contrast you can make much more than 100% if the company does wel

Simply Wall StApr 11 18:46 ET

Ling Rui Pharmaceutical (600285.SH): The company has been re-certified as a high-tech enterprise

Gelonghui, April 10 | Ling Rui Pharmaceutical (600285.SH) announced that it has received a “High-tech Enterprise Certificate” jointly issued by the Henan Provincial Department of Science and Technology, the Henan Provincial Department of Finance, and the Henan Provincial Taxation Bureau of the State Administration of Taxation. The certification of a high-tech enterprise is a re-certification carried out after the expiration of the company's original high-tech enterprise certificate.

Gelonghui FinanceApr 10 03:37 ET

Wu Xizhen, director of Ling Rui Pharmaceutical (600285.SH) and supervisor Li Jin plan to reduce their holdings by no more than 186,000 shares

Ling Rui Pharmaceutical (600285.SH) issued an announcement. Within 6 months after 15 trading days from the date of disclosure of the announcement, Dong...

Zhitong FinanceMar 12 05:06 ET

Retail Investors Who Own 46% Along With Institutions Invested in Henan Lingrui Pharmaceutical Co., Ltd. (SHSE:600285) Saw Increase in Their Holdings Value Last Week

Key Insights Henan Lingrui Pharmaceutical's significant retail investors ownership suggests that the key decisions are influenced by shareholders from the larger public 50% of the business is held b

Simply Wall StMar 9 19:05 ET

Are Robust Financials Driving The Recent Rally In Henan Lingrui Pharmaceutical Co., Ltd.'s (SHSE:600285) Stock?

Henan Lingrui Pharmaceutical's (SHSE:600285) stock is up by a considerable 16% over the past three months. Given that the market rewards strong financials in the long-term, we wonder if that is the

Simply Wall StFeb 20 18:26 ET

Lacklustre Performance Is Driving Henan Lingrui Pharmaceutical Co., Ltd.'s (SHSE:600285) Low P/E

Henan Lingrui Pharmaceutical Co., Ltd.'s (SHSE:600285) price-to-earnings (or "P/E") ratio of 19.1x might make it look like a buy right now compared to the market in China, where around half of the com

Simply Wall StJan 29 18:56 ET

Henan Lingrui Pharmaceutical (SHSE:600285) Sheds 4.1% This Week, as Yearly Returns Fall More in Line With Earnings Growth

The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put in. But on the bright side, if you buy shares in a high quality company at the ri

Simply Wall StDec 19, 2023 21:13 ET